Literature DB >> 1371080

The c-kit receptor ligand functions as a mast cell chemoattractant.

C J Meininger1, H Yano, R Rottapel, A Bernstein, K M Zsebo, B R Zetter.   

Abstract

Mast cells accumulate at sites of neovascularization, solid tumors, and many immune reactions. Such accumulation requires directed migration of mature mast cells or their precursors. The nature of the chemoattractants that regulate mast cell motility and the identity of the receptors that mediate the chemotactic response are poorly understood. We have tested the ability of stem cell factor (SCF), a mast cell growth factor, to stimulate mast cell migration. Our results show that SCF is a potent mast cell attractant that stimulates directional motility of both mucosal and connective tissue-type mast cells. The activity is potentiated by costimulation with interleukin-3 (IL-3), another mast cell chemoattractant. SCF, a known ligand for the c-kit tyrosine kinase receptor, was unable to stimulate motility in W42 mutant mast cells, which have a defective c-kit tyrosine kinase. However, W42 mast cells were still able to migrate in response to IL-3. These results show that SCF is a chemotactic factor as well as a growth factor and that the c-kit receptor can transduce signals leading to both cell proliferation and increased directional cell motility.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1371080

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  61 in total

1.  Mast cell function is not altered by Coronin-1A deficiency.

Authors:  Sanja Arandjelovic; Dilki Wickramarachchi; Saskia Hemmers; Sunamita S Leming; Dwight H Kono; Kerri A Mowen
Journal:  J Leukoc Biol       Date:  2010-07-19       Impact factor: 4.962

Review 2.  Molecular regulation of mast cell development and maturation.

Authors:  Chenxiong Liu; Zhigang Liu; Zhilong Li; Yaojiong Wu
Journal:  Mol Biol Rep       Date:  2009-07-31       Impact factor: 2.316

Review 3.  Allergic eye disease mechanisms.

Authors:  J I McGill; S T Holgate; M K Church; D F Anderson; A Bacon
Journal:  Br J Ophthalmol       Date:  1998-10       Impact factor: 4.638

4.  Phenotypic characterization of skin lesions in urticaria pigmentosa and mastocytomas.

Authors:  N Haas; K Hamann; J Grabbe; B Algermissen; B M Czarnetzki
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

Review 5.  The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others.

Authors:  S J Galli; M Tsai; B K Wershil
Journal:  Am J Pathol       Date:  1993-04       Impact factor: 4.307

6.  Kit signaling through PI 3-kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation.

Authors:  I Timokhina; H Kissel; G Stella; P Besmer
Journal:  EMBO J       Date:  1998-11-02       Impact factor: 11.598

Review 7.  Mast cells and eosinophils: the two key effector cells in allergic inflammation.

Authors:  Yael Minai-Fleminger; Francesca Levi-Schaffer
Journal:  Inflamm Res       Date:  2009-05-08       Impact factor: 4.575

8.  The function of CCR3 on mouse bone marrow-derived mast cells in vitro.

Authors:  Sarah J Collington; John Westwick; Timothy J Williams; Charlotte L Weller
Journal:  Immunology       Date:  2010-01       Impact factor: 7.397

9.  RabGEF1 regulates stem cell factor/c-Kit-mediated signaling events and biological responses in mast cells.

Authors:  Janet Kalesnikoff; Eon J Rios; Ching-Cheng Chen; Susumu Nakae; Brian A Zabel; Eugene C Butcher; Mindy Tsai; See-Ying Tam; Stephen J Galli
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

10.  Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.

Authors:  Patrice Dubreuil; Sébastien Letard; Marco Ciufolini; Laurent Gros; Martine Humbert; Nathalie Castéran; Laurence Borge; Bérengère Hajem; Anne Lermet; Wolfgang Sippl; Edwige Voisset; Michel Arock; Christian Auclair; Phillip S Leventhal; Colin D Mansfield; Alain Moussy; Olivier Hermine
Journal:  PLoS One       Date:  2009-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.